Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PUERTO RICO CHEMICAL INDUSTRY EMPLOYMENT RATE UP 22.4%

Executive Summary

PUERTO RICO CHEMICAL INDUSTRY EMPLOYMENT RATE UP 22.4% since 1980, making it the second fastest growing manufacturing industry in the commonwealth, according to a recent General Accounting Office report. Employment in the chemicals business rose from approximately 15,600 in 1980 to 19,100 in 1988, following only the electrical equipment industry, which rose 26.7% during the eight years. The growth in the chemicals and electrical equipment industries reflects an employment shift from labor-intensive to capital-intensive manufacturing sectors. Among the 15 manufacturing industries cited in the GAO report, only six showed any growth in employment during the eight year period and only chemicals and electrical equipment had gains of more than 6%. Apparel, the largest manufacturing industry, remained static during the period with roughly 33,600 employees. The report, requested by Senate Energy and Natural Resources Committee Chairman Bennett Johnston (D-La.), updates a 1981 review of the political and economic evolution of the commonwealth and the potential effects of changing its political status. Johnston introduced a bill in April that would allow Puerto Rican citizens to choose between statehood, independence or enhanced commonwealth status. The report points out that the shift to capital-intensive manufacturing industries and growth in other segments have resulted in a drop in employment in manufacturing from 20% of total employment in the commonwealth in 1980 to 18% in 1988. Manufacturing, however, is the dominant contributor to the island's income, generating $ 9.4 bil. (62% of total net income) in 1988. "Spurred almost entirely by investments of U.S. firms, manufacturing has become the most important sector in Puerto Rico's economy," GAO observed. (PARAGRAPH)Despite improvement in Puerto Rico's economic condition in recent years, the report observes that "new jobs will need to be created in the future to improve the standard of living and the employment rate." In 1988, the island's per capita personal income was $ 5,157, less than half that of Mississippi, the state with the lowest per capita income. The report observes that the Section 936 tax credit is "one of the most significant tax provisions affecting Puerto Rico." Sen. Pryor (D-Ark.) has been the most recent critic in Congress of Section 936 tax breaks for pharmaceutical companies with operations in Puerto Rico. At a July 18 hearing on drug pricing, for example, the Senate Aging Committee chairman questioned the industry's defense of high R&D costs by pointing to Section 936 and other tax breaks ("The Pink Sheet" July 24, p. 4). In a recent statement on the Senate floor on prescription drug prices, Pryor said pharmaceutical companies' taxes have dropped 27% over the last four years. "The Treasury Department's revenue loss for tax incentives to employ Puerto Rican pharmaceutical company workers is more than six times larger than those for the high-tech industry, and 19 times larger than those for apparel makers," he pointed out.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS016149

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel